Medication misadventures: How to minimize them?;Acidentes com os medicamentos: Como minimizá-los?

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 42, Issue 4, 2006, Pages 487-495

  Kawano, Daniel Fábio ^a   Pereira, Leonardo Régis Leira ^a   Ueta, Julieta Mieko ^a   De Freitas, Osvaldo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Faculdade de Ciências Médicas de Minas Gerais   (Brazil)

Author keywords

Medication mistakes; Medicine interactions; Side effects

Indexed keywords

DRUG SAFETY; DRUG USE; HEALTH HAZARD; HEALTH SERVICE; INFORMATION PROCESSING; MEDICAL PRACTICE; MEDICATION ERROR; PRESCRIPTION; REVIEW;

EID: 33947662589     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-93322006000400003     Document Type: Review

References (48)

1. AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS. Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am. J. Hosp. Pharm., v. 55, p. 165-166, 1998.
2. BATES, D.W.; SPELL, N.; CULLEN, D.J.; BURDICK, E.; LAIRD, N.; PETERSEN, L.A. The costs of adverse drug events in hospitalized patients. J. Am. Med. Assoc., v. 277, n. 4, p. 307-311, 1997.
3. BATES, D.W.; LEAPE, L.L.; CULLEN, D.J.; LAIRD, N.; PETERSEN, L.A.; TEICH, J.M. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. J. Am. Med. Assoc., v. 280, n. 5, p. 1311-1316, 1998.
4. BATES, D.W.; COHEN, M.; LEAPE, L.L.; OVERHAGE, J.M.; SHABOT, M.M.; SHERIDAN, T. Reducing the frequency of errors in medicine using information technology. J. Am. Med. Inform. Assoc., v. 8, n. 4, p. 299-308, 2001.
5. BATES, D.W.; GANDHI, T.K.; KAUSHAL, R. Introdução à segurança do paciente. In: CASSIANI, S.H.B; UETA, J.M. A segurança dos pacientes na utilização da medicação. São Paulo: Artes Médicas, 2004. 5 p.
6. BIRKMEYER, C.M.; LEE, J.; BATES, D.W.; BIRKMEYER, J.D. Will electronic order entry reduce health care costs? Eff. Clin. Pract., v. 5, n. 2, p.67-74, 2002.
7. BLASCHKE, T. F.; COHEN, S. N.; TATRO, D. S. Drug-drug interactions and aging. In: JARVIK, L. F.; GREENBLATT, D. J.; HARMAN, D. Clinical Pharmacology in the Aged Patient. New York: Raven, 1981. p.11-26.
8. BORDA, I.T.; SLONE, D.; HICK, H. Assessment of adverse reactions within a drug surveillance program. J. Am. Med. Assoc., v. 205, p. 645-647, 1968.
9. BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM. Adverse drug interactions. J. Am. Med. Assoc., v. 220, p. 1238-1239, 1972.
10. CLASSEN, D.C.; PESTOTNIK, S.L.; EVANS, R.S.; LLOYD, J.F.; BURKE, J.P. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. J. Am. Med. Assoc., v. 277, n. 4, p. 301-306, 1997.
11. DAVIES, D.M. 2000 years of adverse drug reactions. Adv. Drug React. Bull, v. 199, p. 759-762, 1999.
12. DURRENCE, C.W.; DIPIRO, J.T.; MAY, J.R. Potential drug interactions in surgical patients. Am. J. Hosp. Pharm., v. 42, p. 1553-1555, 1985.
13. GALANTER, W.L.; DIDOMENICO, R.J.; POLIKAITIS, A. Preventing exacerbation of an ADE with automated decision support. J. Health. Inf. Manag., v. 16, n. 4, p. 44-49, 2002.
14. GRAHAME-SMITH, D.G.; ARONSON, J.K. Oxford textbook of clinical pharmacology and drug therapy. 3 ed. Oxford: Oxford University Press, 2002. p.83-109.
15. HANSTEN, P.D.; HORN, J.R. Pharmacokinetic drug interaction mechanisms and clinical characteristics. In:_. Drug interactions & updates. Vancouver: Applied Therapeutics, 1994. p.1-24.
16. HEPLER, C.D.; STRAND, L.M. Opportunities and responsibilities in pharmaceutical care. Am. J. Hosp. Pharm., v. 47, p. 533-543, 1990.
17. JANKEL, C.A.; MCMILLAN, J.A.; MARTIN, B.C. Effects of drug interactions on outcomes of patients receiving warfarin or theophylline. Am. J. Hosp. Pharm., v. 51, p. 661-666, 1994.
18. JOHNSON, J.A.; BOOTMAN J.L. Drug-related morbidity and mortality: a cost-of-illness model. Arc. Int. Med., v. 155, n. 18, p. 1949-1956, 1995.
19. KASTRUP, E.K. Drug facts and comparisons. St. Louis: Facts and Comparisons, 2004. 2200 p.
20. KAUSHAL, R.; BATES, D.W. Computerized Physician Order Entry (CPOE) with Clinical Decision Support Systems (CDSSs). In: SHOJANIA, K.G.; DUNCAN, B.W.; McDONALD, K.M.; WACHTER, R.M., (Eds). Making health care safer: a critical analysis of patient safety practices. Rockville: Agency for Healthcare Research and Quality, 2001. p.59-69.
21. (Evidence Report/Technology Assessment No. 43) (AHRQ Publication No. 01-E058).
22. KOHN, L.T.; CORRIGAN, J.M.; DONALDSON, M.S. To err is human: building a safer health system. Washington: National Academy of the Institute of Medicine, 1999. 496 p.
23. LAZAROU, J.; POMERANZ, B.; COREY, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc., v. 279, p. 1200-1205, 1998.
24. LEAPE, L.L.; BATES, D.W.; CULLEN, D.J.; COOPER, J.; DEMONACO, H.J.; GALLIVAN, T.; HALLISEY, R.; IVES, J.; LAIRD, N.; LAFFEL, G. Systems analysis of adverse drug events: ADE Prevention Study Group. J. Am. Med. Assoc., v. 274, n. 1, p. 35-43, 1995.
25. LEAPE, L.L.; CULLEN, D.J.; CLAPP, M.D.; BURDICK, E.; DEMONACO, H.J,; ERICKSON, J.I. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. J. Am. Med. Assoc., v. 282, p. 267-270, 1999.
26. LEASER, T.S. Recommendations for Reducing Medication Errors. Medscape pharmacists, 2000. Disponível em: 〈http://www.medscape.com/ viewarticle/408566〉. Acesso em: 14 ago. 2004.
27. LEFEVRE, F. O medicamento como mercadoria simbólica. São Paulo: Cortez, 1991. 208 p.
28. LIEDER, T.R. Computerized prescriber order entry changes pharmacists' roles. Am. J. Health-System Pharm., v. 58, n. 10, p. 846-851, 2001.
29. MANASSE JUNIOR, H.R. Medication use in a imperfect world: drug misadventuring as an issue of public policy, part 1. Am. J. Hosp. Pharm., v. 46, n. 5, p. 929-944, 1989.
30. MANT, A. Pharmaceutical health promotion: a new concept in therapeutics. Soc. Sci. Med., v. 39, p. 305-306, 1994. [Editorial].
31. MAY, R.J. Adverse drug reactions and interactions. In: DIPIRO, J.T.; TALBERT, R.L.; HAYES, P.E.; YEE, G.C.; MATZKE, C.R.; POSEY, L.M. Pharmacotherapy: a pathophysiologic approach. Norwalk: Appleton & Lange, 1997. p.101-116.
32. McDONALD, C.J. Protocol-based computer reminders, the quality of care and the non-perfectability of man. New Eng. J., v. 295, p. 1351-1355, 1976.
33. McINNES, G.T.; BRODIE, M.J. Drug interactions that matter: a critical reappraisal. Drugs, v. 36, p. 83-110, 1988.
34. NATIONAL COORDINATING COUNCIL FOR MEDICATION ERROR REPORTING AND PREVENTION. Taxonomy of medication errors -1998-1999. Disponível em: 〈http://www.nccmerp.org/public/ aboutmederror.htm〉. Acesso em: 22 out. 2003.
35. OPPENHEIM, M.I.; VIDAL, C.; VELASCO, F.T.; BOYER, A.G.; COOPER, M.R.; HAYES, J.G. Impact of a computerized alert during physician order entry on medication dosing in patients with renal impairment. In: AMERICAN MEDICAL INFORMATICS ASSOCIATION (AMIA) ANNUAL SYMPOSIUM, 2002, San Antonio, TX. Symposium. San Antonio: Proceedings of AMIA, 2002. p.577-581.
36. ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Report on a symposium in Oslo. Consumption of drugs. Copenhagem, Denmark: OMS, 1969. p. 3-7.
37. ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). The WHO Technical Report Series No. 498. International drug monitoring: the role of national centers. Genebra, Suíça: OMS, 1972. p. 498.
38. ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). The WHO Technical Report Series No. 615. The selection of essential drugs. Genebra, Suíça: OMS, 1977. p. 44.
39. ORGANIZAÇÃO MUNDIAL DA SAÚDE. El papel del Farmacéutico en el sistema de atención de salud. ARS Pharm., v. 36, p. 285-292, 1995.
40. PECK, C.C.; ROOMAN, J.H. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In: EVANS, W.E.; SCHENTAG, J.J.; JUSKO, W.J. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2 ed. Spokane: Applied Therapeutics, 1986. p. 55-82.
41. PENNA, R. P. Pharmaceutical care: pharmacy's mission for the 1990s. Am. J. Hosp. Pharm., v. 47, p. 543-549, 1990.
42. RANG, H.P.; DALE, M.M.; RITTER, J.M. Pharmacology. 4 ed. New York: Churchill Livingstone, 2000. 633 p.
43. STANASZEK, W.F.; FRANKLIN, C.E. Survey of potential drug interaction incidence in an outpatient clinic population. Hosp. Pharm., v. 13, p. 255-263, 1978.
44. STROM, B.L. What is pharmacoepidemiology? In:_. Pharmacoepidemiology. New York, Churchill Livingstone, 1989. p.3-12.
45. TATRO, D. S. Textbook of therapeutics, drug and disease management. 6 ed. Baltimore: William and Wilkins, 1996. p.33-44.
46. WEATHERALL, M. In search of a cure: A history of pharmaceutical discovery. Oxford: Oxford University Press, 1990. 16 p.
47. WINTERSTEIN, A.G.; HATTON, R.C.; GONZALEZ-ROTHI, R.; JOHNS, T.E.; SEGAL, R. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am. J. Health-Syst. Pharm., v. 59, n. 18, p. 1742-1749, 2002.
48. WROBLEWSKI, B. The Cytochrome P-450 drug metabolizing enzyme system: an overview of potential clinically important drug interactions. J. Head Trauma Rehabil., v. 17, n. 6, p. 571-574, 2002.